David Rubenstein, the co-founder of the Carlyle Group and host of “Leadership Live,” discusses the current scope of the U.S. stock market and employment.
from Yahoo Finance https://ift.tt/32nj0jO
(Bloomberg) — Oil retreated from its highest close in four months after the OPEC+ alliance confirmed it would start tapering output cuts from next month.Futures in New York dropped below $41 a barrel. Saudi Arabia and Russia said the producer bloc would proceed with its plan to add more supply next month and were confident that it wouldn’t hurt oil’s rally, with the tapering to be offset by extra cuts from countries that didn’t meet their targets.Oil was also under pressure from a drop in equities in Europe and Asia. That was despite figures that showed China’s economy returned to growth and expanded more than forecast last quarter.The recovery in China is in stark contrast to other corners of the globe, where the coronavirus continues to rage out of control. That’s leading to a patchy rebound in crude, though there are pockets of strength in some parts of the oil market, with North Sea contracts trading at their strongest levels in five months. All of that has left headline prices struggling to break far beyond $41.“Unless the market makes a convincing jump today, those with bullish inclination will become disillusioned and the recent highs will not be challenged in the near future,” said Tamas Varga, an analyst at brokerage PVM Oil Associates.The Organization of Petroleum Exporting Countries and its allies will withhold 7.7 million barrels a day from the market in August, compared with 9.6 million currently. The actual cut next month will be 8.1 million to 8.3 million barrels a day due to the compensatory curbs from members including Iraq and Nigeria.See also: U.S. Gasoline Stocks Mirror Nation’s Fractured Pandemic ResponseThere were also signs that supplies from Russia will remain low, at least in the short-term. It will ship three cargoes of Urals crude from its Baltic ports in the first five days of August, down from five a month earlier, according to a loading program. Urals loadings were planned at the lowest in a decade for July.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/3h2S2Cc
Shares in Dell Technologies (DELL) surged 7% in pre-market trading as the PC maker said that it is considering a spin-off of its 81% stake in cloud computing software maker VMware Inc. (VMW), which could unlock value for shareholders.The stock soared to $56.40, while VMware rose 1.9% to $142.40 in Thursday’s early market trading. Dell said that a divestment could benefit both Dell and VMware shareholders by simplifying capital structures and creating additional long-term enterprise value. A potential spin-off is not expected to occur before Sept. 2021 and would qualify to become tax-free for U.S. tax purposes.If the PC maker decides to pursue a spin-off, it would set up a special committee to negotiate mutually beneficial commercial arrangements, including intellectual property agreements. In that event Dell would seek to negotiate the payment of a special cash dividend by VMware that would be paid on a pro rata basis to all VMware shareholders."For more than 20 years, we've innovated for our customers and created substantial growth and value for both companies and our teams. Regardless of the options we are exploring to create additional value, we are accelerating our strategy – which remains unchanged,” said Dell CEO Michael Dell. “We are focused on winning in the consolidating markets where we operate and innovating across the Dell portfolio to create integrated solutions that turn data into insights and action.”Dell added though that it continues to evaluate a range of strategic options concerning its ownership interest in VMware, including holding on to its current ownership in the company.Meanwhile, five-star analyst Daniel Ives at Wedbush, said that the Dell-VMware “soap opera” has been a multi-year ownership structure partnership that has been a “frustration point” for investors since EMC sold its 81% stake to Dell in 2015.“The likely path in our opinion and the one most appetizing to investors would be a tax-free spinoff for this stake,” Ives wrote in a note to investors. “The Dell ownership structure has been an albatross around the VMware story and ultimately causes the stock to trade at a discount, a dynamic that would be removed if Dell ultimately decided to head down this path.”Ives estimated that if Dell did not own VMware this would add $15 to $20 per share as he expects a positive knee jerk reaction from investors. However, the analyst cautioned that it was too early to pop the champagne yet as there could be many twists and turns in this strategic relationship which could potentially end with no deal at all.Ives maintains a Buy rating on VMware stock with a $175 price target given its “position in the cloud evolution with an expanding product footprint that could see an acceleration of growth for the coming years”.Overall, analysts have a cautiously optimistic outlook on the stock. The Moderate Buy consensus shows 12 Buy ratings vs 6 Hold ratings. The $170.67 average analyst price target implies 22% upside potential over the coming year. (See VMW stock analysis on TipRanks).Related News: Google Snaps Up 7.7% Stake In India’s Jio Platform For $4.5B Intel Capital Snaps Up $255M Stake In India’s Jio Platforms Medtronic To Buy Medicrea For About $154 To Bolster Spine Surgery Business More recent articles from Smarter Analyst: * AstraZeneca Pops Ahead of Covid-19 Vaccine Data Report Due July 20 * Beyond Meat Shares Rise On Sale Of Plant-Based Meat In Brazil * Facebook To Increase Oculus Production To 2 Million Units- Report * Google Expands Android Subscription Service To Nine More Countries
from Yahoo Finance https://ift.tt/30fZz9Z
Tesla Inc (NASDAQ: TSLA) car sales in California plunged by nearly a half in the quarter ending June, according to data released by marketing research company Cross-Sell on Wednesday.What Happened Vehicle registrations for the Elon Musk-led company fell nearly 48% to 9,774 units between April and June in the Golden State, compared with a similar period a year earlier, Cross-Sell said, as reported by Reuters.Registrations of Model 3, which is the cheapest vehicle in Tesla's lineup, fell 63% to 5,951 units.Total vehicle registrations fell across the 23 states, where the data was gathered, by approximately 49% to 18,702 vehicles.Registration data may not be a true representation of delivery numbers during the quarter as it takes almost 30 days for vehicles to be registered from the time they are sold in the United States, Reuters noted.Why It Matters The majority of the U.S. was under lockdown in the period between April to June to prevent the spread of COVID-19, which affected both production and auto sales in the country.Production at Tesla's Fremont factory, in California, was suspended between March and May due to the pandemic. Tesla revealed earlier this month it delivered 90,650 vehicles in the second quarter this year. The disclosure by the Palo Alto-based automaker indicates that it had restored production to levels as they existed before the shutdown.Price Action On Wednesday, Tesla shares traded 2.26% lower at $1,511 in the after-hours. The shares had closed the regular session 1.93% higher at $1,546.01.See more from Benzinga * Tesla To Debut In India By 2021, Expects Roth Capital's Irwin, Raises Price Target * Tesla Share Frenzy Means Elon Musk May Enjoy .8B Personal Windfall * Tesla Website Crashes As Musk Puts 'Short Shorts' On Sale(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
from Yahoo Finance https://ift.tt/3fFRPVq

Buy and hold investing may not be an exciting get-rich-quick strategy, but it has the potential to generate significant wealth over the long term.
Some of the world’s richest people, such as legendary investor Warren Buffett, have used this strategy to build their fortunes and there is nothing to stop the average investor from doing the same.
With that in mind, here are two ASX shares that I think would be excellent buy and hold options:
I think that this ecommerce company could be a great buy and hold option. Over the last few years it has been benefiting greatly from the shift to online shopping. Pleasingly, this shift has accelerated because of the pandemic. Perhaps even more than you might think. Adobe estimates that the pandemic has accelerated ecommerce growth by 4 to 6 years.
If this proves to be the case, then it is likely to underpin exceptionally strong earnings growth for Kogan in FY 2020 and FY 2021. Though, management isn’t settling for that. It recently raised $120 million to fund the potential acquisitions of businesses that it believes will add value and drive further growth.
ResMed is another ASX share which I would buy and hold. I think the medical device company is a great buy and hold option due to the proliferation of obstructive sleep apnoea (OSA). Management estimates that just 20% of OSA sufferers have been diagnosed at this point, but I expect that to change in the future as education around the sleep disorder increases.
And thanks to the quality of its products and software, I’m confident ResMed will capture a greater slice of this growing market over the next decade. Overall, I expect this to support strong earnings growth for years to come and drive the ResMed share price notably higher over the 2020s.
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd. The Motley Fool Australia has recommended Kogan.com ltd and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Invest like Warren Buffett and buy and hold these excellent ASX shares appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3j80jGG
Shares in AstraZeneca (AZN) spiked almost 5% in after-market trading amid a report that early-stage human trial data on the drugmaker’s coronavirus vaccine candidate will be disclosed on July 20.The stock rose to $60.60 in Wednesday’s extended trading after earlier jumping 7%. Data results from the Phase 1 trial of the potential coronavirus vaccine, also known as AZD1222, which AstraZeneca is developing with Oxford University, are slated to be published on Monday, according to the Lancet medical journal.The data is expected to demonstrate whether the potential vaccine is safe and whether or not it triggers an immune response. Earlier this month, the vaccine developers said they were encouraged by the immune response they had seen in trials so far.“We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release,” a spokeswoman for the journal told Reuters.Meanwhile, the vaccine candidate is already in large-scale Phase III human trials to assess whether it can protect against COVID-19.AstraZeneca has in recent weeks signed supply chain agreements for the capacity to produce 2 billion doses of its vaccine candidate. The British drugmaker has inked supply deals with the U.S. and European Union countries.AZD1222 is one of several candidates supported by Operation Warp Speed (OWS), the U.S. government program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines available for Americans by Jan. 2021.Shares have jumped 53% since mid-March as AstraZeneca joined the list of companies engaged in the development of a potential coronavirus vaccine. Despite the recent rally, the $61.67 average analyst price target still puts the upside potential at 6.3% in the coming 12 months. (See AstraZeneca stock analysis on TipRanks)Overall, the stock scores a Strong Buy consensus from the analyst community based on 4 unanimous Buy ratings.Related News: AstraZeneca’s Wins FDA Priority Review For Heart Drug Brilinta Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate Is Moderna (MRNA) Stock Still Worth Buying After Its Huge Rally? JPMorgan Says Yes More recent articles from Smarter Analyst: * Beyond Meat Shares Rise On Sale Of Plant-Based Meat In Brazil * Facebook To Increase Oculus Production To 2 Million Units- Report * Google Expands Android Subscription Service To Nine More Countries * Google Brings 5 Game Studios To Stadia To Make Exclusive Games
from Yahoo Finance https://ift.tt/32n2m3P

Due to the expected growth in demand for healthcare services globally because of ageing populations, improving technologies, and increasing chronic disease burden, I believe the healthcare sector is a great place to invest with a long-term view.
But with so many options to choose from in the sector, it can be hard to decide which ones to buy.
To narrow things down I have picked out three ASX healthcare shares I think could be long-term market beaters:
I believe this biotherapeutics company is well-positioned for long term growth. This is due to the quality of its CSL Behring and Seqirus businesses. Both are leaders in their industries, have world class product portfolios, and lucrative product development pipelines. This pipeline is underpinned by the company investing 10% to 11% of sales into research and development activities each year. For example, in FY 2019 CSL invested US$832 million into research and development. Management believes these investments are the engine that will help drive sustainable growth and I completely agree.
Another ASX healthcare share to consider buying with a long term view is Pro Medicus. It is a leading provider of a full range of radiology IT software and services to hospitals, imaging centres, and healthcare groups. It has been growing at a very strong rate over the last few years thanks to growing demand for its offering from a number of leading healthcare institutions. Given the quality of its products and its sizeable market opportunity, I believe Pro Medicus is capable of continuing this strong form for some time to come.
A final ASX healthcare share to buy is Ramsay Health Care. It is a leading private hospital operator with 480 facilities across 11 countries. This makes it one of the largest and most diverse private healthcare companies in the world. I believe this puts Ramsay in a great position to capture the growing demand for healthcare services globally once trading conditions return to normal following the pandemic.
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why these excellent ASX healthcare shares could be long-term market beaters appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/32neFx5
(Bloomberg) — The rally in Chinese shares is unraveling almost as quickly as it began, with losses accelerating Thursday after state media criticized one of the country’s most popular stocks.The CSI 300 Index closed 4.8% lower, its biggest loss since markets reopened in February following the Lunar New Year break. Crowd favorite Kweichow Moutai Co. slumped 7.9%, wiping out a record $25 billion in value and dragging down an index of consumer shares by the most since 2018. The ChiNext Index, which had earlier this week turned hotter than any benchmark in the world, fell as much as 6.2%.This month’s frenzy in Chinese stocks had pushed the value of the country’s equity market to almost $10 trillion, a level that marked the top of the bubble five years ago. Policy makers have since taken steps to rein in speculation in equities, including effectively withdrawing liquidity from the financial system.The impact showed in Wednesday’s smallest increase in stock leverage since late June. The CSI 300, which was up almost 17% for the month on Monday, has now given up half those gains.An attack from the People’s Daily newspaper on Moutai was taken as another sign of Beijing’s desire to slow the recent run-up, after government-backed funds sold shares or announced plans to so in the past few days. Increasing tensions with the U.S., the central bank’s clampdown on easy money and a drop in retail sales are also adding up as reasons to start selling.Data Thursday showed the Chinese economy returned to growth in the second quarter, expanding a better-than-expected 3.2%. While industrial output rose 4.8% from a year earlier, retail sales shrank 1.8%, weaker than a projected 0.5% increase. That suggests the recovery is still largely industry-driven, with consumer sentiment remaining fragile.“Retail sales came worse than expected, which hurts sentiment towards some consumer stocks,” said Daniel So, a strategist at CMB International Securities Ltd. “A stabilizing economy means the scale of monetary easing may be smaller than expected. Ample liquidity was one of the key reasons for markets to jump.”Overseas investors continued to trim their holdings of mainland-listed shares, selling nearly $4 billion worth of the stocks through exchange links in the past three days.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/3h7JES6

The S&P/ASX 200 Index (ASX: XJO) fell by 0.7% today to 6,011 points.
COVID-19 continues to spread in the south east of the country. Victoria announced another 317 confirmed cases – the largest increase since the start of the pandemic. Meanwhile, NSW announced 10 more COVID-19 cases. Four of them were in hotel quarantine, three were associated with the Crossroads Hotel and another three are ‘under investigation’.
The latest employment stats from the Australia Bureau of Statistics (ABS) were a mixed bag.
Australia’s unemployment rate increased from 7.1% in May to 7.4% in June, with an additional 69,300 people unemployed. However, on the plus side there were also an extra 210,800 more people employed. This included 38,100 less full time employees and 249,000 more part-time employees.
The share price of ASX 200 employment site SEEK Limited (ASX: SEK) rose by 1% today and the Commonwealth Bank of Australia (ASX: CBA) share price fell 0.1%.
Beauty business BWX is launching a capital raising to fund the development and construction of a new manufacturing facility and support office. The facility is expected to be earnings per share (EPS) accretive in FY23 and onwards.
It’s going to be funded by a fully underwritten institutional placement of $40 million at a share price of $3.40. This price is a 7.1% discount to the last closing price of $3.66.
The facility should result in improved labour productivity and efficiency improvements, material waste reduction of around 50% and material cost reduction.
BWX also announced some unaudited FY20 numbers. Revenue increased by 25% to $187.6 million. Earnings before interest, tax, depreciation and amortisation (EBITDA) (pre-AASB 16) rose by 30% to $27.5 million. The gross profit margin increased to 58%. Net debt improved from $42.8 million last year to $32 million at 30 June 2020.
BWX Chief Operations Officer Mr Rory Gration said: “This world class facility is expected to significantly boost BWX’s in-house manufacturing capacity, capability and competitive advantage; provide up-skilling opportunities for our team; enhance the ways in which we serve our retail partners, customers and consumers all over the world.”
Medibank announced this afternoon that it has resolved Australian Competition and Consumer Commission proceedings regarding ahm’s boost and lite products with the federal court approving the agreed settlement with the ACCC.
The ACCC has also accepted an enforceable undertaking offered by the ASX 200 private health insurer.
These proceedings relate to representations made by ahm when responding to claims and eligibility enquires by customers for joint investigations and reconstruction procedures under ahm’s boost and lite products.
Medibank will pay a $5 million penalty as well as a payment of $400 to customers who have not yet submitted or have not received payment for a claim of compensation. This payment is expected to be made to around 670 customers.
The Medibank share price fell 1.3%, but it wasn’t one of the worst performers in the ASX. That was Breville Group Ltd (ASX: BRG).
The Beacon share price went up almost 10% today after giving a trading update for FY20.
Reported sales were $252 million, an increase of 2.6%. Underlying sales, excluding Beacon Energy Solutions, amounted to $251 million – this was growth of 8%. Company stores achieved comparative sales growth of 7.2%. Online sales growth was 50.6%.
Reported FY20 net profit after tax is expected to be approximately $22 million, representing growth of 38.5%. Underlying net profit after tax is expected to be around $19 million, up 16.7%. The underlying profit measure excludes the Parkinson Distribution Centre sale, the AASB 16 lease accounting changes and Beacon Energy Solutions.
Beacon Lighting CEO Glen Robinson said: “Despite the disruptive times over the second half of FY20, the group has been able to achieve outstanding results. These results would not have been possible if it was not for our adaptable and resilient team at Beacon Lighting and the continued support of our valued customers. Our ongoing commitment to innovate the lighting and ceiling fan categories, ensures our customer receive the latest products.”
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended BWX Limited. The Motley Fool Australia has recommended SEEK Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Market close: ASX 200 drops 0.7% today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2CBB8Ma